BIOPHARMA
By
Is Merck and Nvidia’s KERMT Model the Breakthrough That Finally Makes AI-Native Drug Discovery Faster, Greener, and More Predictive?
Key Highlights / Executive Takeaways: • Merck and Nvidia introduce KERMT, a next-generation small-molecule AI model trained on…
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance Accelerate the Next Wave of Antibody and NANOBODY® Innovation in Inflammatory Diseases?
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi, reinforcing AI/ML as…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
Is Pfizer Facing New Safety Scrutiny After Reporting a Patient Death in Its Hympavzi Hemophilia Trial?
Pfizer has disclosed that a patient enrolled in a clinical trial evaluating its investigational hemophilia treatment Hympavzi died…
How Is Pfizer Expanding Its Oncology Pipeline Through T-Cell–Targeted Immunotherapy for Prostate Cancer?
Cambridge, Massachusetts Pfizer is strengthening its oncology research pipeline through a new program launched under its strategic collaboration…
